United States: EDTX & NDTX Monthly Wrap-Up – April 2019

Last Updated: May 29 2019
Article by Andria Rae Crisler and Lance Wyatt

A Tale of Two ANDAs: Jurisdiction and Venue in a Non-Traditional Sense

Judge Gilstrap's recent opinion in Apicore US LLC v. Beloteca, Inc., No. 2:19-CV-00077-JRG, 2019 WL 1746079 (E.D. Tex. Apr. 18, 2019), highlights interesting personal jurisdiction and venue issues in a non-traditional pharmaceutical suit involving patents asserted by an ANDA filer against another ANDA filer. With respect to personal jurisdiction, the court found sufficient minimum contacts based on the Federal Circuit's Acorda decision even though the defendant had not submitted a Paragraph IV certification. Nevertheless, Judge Gilstrap transferred the case to the Northern District of Illinois on the basis of improper venue under 28 U.S.C. § 1400(b).

Unlike traditional Hatch-Waxman disputes where the plaintiff is the holder of an NDA and lists patents in the FDA's Orange Book, no party in Apicore holds the NDA. In other words, the asserted patents are not listed in the Orange Book.1 Here is a brief timeline of the events that led to this case:

  1. In 1981, Hirsch Industries and its successor-in-interest Covidien Ltd. developed and commercialized a 1% injectable solution of (isosulfan blue ("ISB")) under the trade name Lymphazurin.2 Covidien, the original NDA holder, listed various patents in the Orange Book covering Lymphazurin.3 Covidien met with many difficulties in synthesizing and purifying ISB.4
  2. In the early 2000s, Apicore partnered with a predecessor to Mylan Institutional to develop and market a generic version of Lymphazurin.5
  3. Plaintiff Apicore developed an improved process to manufacture highly pure ISB and acquired patents related to that process including the patents-in-suit.6 Apicore filed an ANDA on its generic Lymphazurin, which the FDA approved in 2010.7 Co-plaintiff Mylan is the exclusive license to the patents-in-suit.8 As neither Apicore nor Mylan were the NDA filer, neither company was required to (and did not) submit the patents-in-suit to the FDA for addition to the Orange Book.9
  4. In 2011, Covidien withdrew Lymphazurin from the market.10
  5. In 2017, Defendant Beloteca filed an ANDA to market an ISB injection product, which FDA approved in 2019.11 Because the patents-in-suit were not listed in the Orange Book, Beloteca did not submit a Paragraph IV certification with its ANDA.12
  6. The day after its ANDA was approved, Beloteca filed a declaratory judgment action for non-infringement and invalidity against Apicore and Mylan in the Northern District of Illinois.13
  7. Two months later, Apicore and Mylan filed a declaratory judgment suit for infringement against Beloteca in the Eastern District of Texas.14
  8. Beloteca sought to dismiss the E.D. Texas case for lack of personal jurisdiction or improper venue.15

Personal Jurisdiction

The parties' arguments on personal jurisdiction centered on the Federal Circuit's opinion in Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc., 817 F.3d 755 (Fed. Cir. 2016). In Acorda, a traditionally-postured Hatch-Waxman case, the Federal Circuit found sufficient contacts to support personal jurisdiction in Delaware where a non-Delaware ANDA filer did not dispute that it would market and distribute its generic products throughout the country, including in Delaware, if approved.16

Mylan argued that the reasoning in Acorda applied equally in the present case.17 Specifically, Mylan argued that like the defendant in Acorda, Beloteca's filing of an ANDA in combination with its plans to market its ISB product nationwide were sufficient to support personal jurisdiction.18 Judge Gilstrap agreed, finding Beloteca had sufficient contacts with the Eastern District of Texas in light of its ANDA filing and approval as well as Beloteca's intent to sell its ISB product through a third-party with an established distribution network in Texas.19

Judge Gilstrap rejected Beloteca's two arguments against personal jurisdiction. First, Beloteca argued that in the absence of a Paragraph IV certification, Mylan's declaratory judgment action was not a Hatch-Waxman case, seemingly removing the jurisdiction analysis from the Acorda framework.20 Judge Gilstrap disagreed, finding that "paragraph IV certification is not required to sustain a § 271(e)(2) infringement claim."21 Second, Beloteca argued that an ANDA filing cannot be the sole basis for jurisdiction, and Acorda is limited to defendants with existing distribution networks.22 But the court held that the ANDA filing and Beloteca's third-party agreement for future distribution of the products satisfied minimum contacts.


Despite his finding of personal jurisdiction, Judge Gilstrap nevertheless concluded that venue in the Eastern District of Texas was improper under § 1400(b) because Beloteca is a California corporation having a place of business in San Diego, California. Mylan argued that because it filed its action as a declaratory judgment action for future patent infringement, the more permissive venue provisions of § 1391 governed.23 But having already found that Mylan had a cognizable claim under § 271(e)(2), the court rejected this argument as an end-run around § 1400(b).24 Mylan could therefore not avoid TC Heartland and made no argument that venue was proper under the standards set forth in TC Heartland.25

Questions Raised by Apicore

1. Can a plaintiff sustain a claim under § 271(e) without a Paragraph IV certification?

Although Judge Gilstrap held that a Paragraph IV certification is not required to support a claim under § 271(e), his opinion in Apicore acknowledges that other district courts have reached the opposite conclusion. Indeed, this question is far from settled.26 In the context of jurisdiction, as Judge Gilstrap noted, this question seems to be more applicable to subject matter jurisdiction inquires, which were not at issue in Apicore.27 Judge Gilstrap noted that "whether Plaintiffs have a cognizable claim under § 271(e) due to [the] . . . lack of a paragraph IV certification [in Beloteca's ANDA] has little bearing on this Court's personal jurisdiction over Beloteca."28

In Apicore, however, this question appeared to have a significant impact on the venue inquiry. Judge Gilstrap's opinion highlights the inequities in venue selection between plaintiffs and defendants in Hatch-Waxman cases following TC Heartland. The general venue statute, § 1391, apparently governed Beloteca's earlier filed declaratory judgment action in the Northern District of Illinois,29 but Judge Gilstrap found the mirror version of Beloteca's case filed by Apicore in the Eastern District of Texas was governed by the stricter patent venue statute, § 1400(b). The same situation would presumably arise where an ANDA filer pursues a declaratory judgment of non-infringement and invalidity against an NDA or patent holder pursuant to § 271(e)(5) in the absence of an earlier filed suit by the patent holder.

Venue issues in Hatch-Waxman cases following TC Heartland and Acorda have come up in other cases as well, resulting in at least one district court split.30 Compare Galderma Labs., L.P. v. Teva Pharm. USA, Inc., 290 F. Supp. 3d 599, 608 (N.D. Tex. 2017) (declining to find "that an act of infringement occurs wherever an ANDA filer intends to market the accused product" and finding venue improper on that basis) with Bristol-Myers Squibb Co. v. Mylan Pharm. Inc., No. CV 17-379-LPS, 2017 WL 3980155, at *13 (D. Del. Sept. 11, 2017) ("[A]n applicant's submission of an ANDA . . . can be sufficient to demonstrate that the ANDA-filing Defendant 'has committed' 'acts of infringement' in this District."). Further attention from both Congress and the Federal Circuit is necessary to tie-up the loose ends in Hatch-Waxman venue selection created by TC Heartland.

2. Does Acorda apply in non-traditional pharmaceutical patent cases?

While Apicore is not a traditional Hatch-Waxman case between an NDA holder and an ANDA filer, Judge Gilstrap nevertheless applied the Federal Circuit's Acorda decision. Although Acorda was a traditional Hatch-Waxman case involving an NDA holder and an ANDA filer and the Federal Circuit relied heavily on the Hatch-Waxman Act to support its conclusion in Acorda, the Federal Circuit ultimately based its finding of personal jurisdiction on (1) the defendant's ANDA filing and (2) the defendant's intent to distribute its generic products. Both factors were present in Apicore and would have remained so even if Judge Gilstrap had found Mylan did not have a claim under § 271(e). Other courts could find, however, that these factors have specific implications solely in the realm of traditional Hatch-Waxman cases, which "recognize[] the close connection between an ANDA filing and the real-world acts that approval of the ANDA will allow and that will harm patent-owning brand-name manufacturers."31

3. Has Acorda shifted the burden to show minimum contacts to defendants?

While the initial burden of showing minimum contacts lies with the plaintiff, Acorda and its progeny marks a slight shift in this burden to defendants. In both Acorda and Apicore, the defendants had entered into agreements with third-parties to distribute their proposed drugs. But both courts focused on the absence of a dispute that the defendants intended nationwide distribution to establish that intent. And the Federal Circuit in Acorda went into great detail on the substantial costs of preparing and filing an ANDA submission to support future marketing and distribution "in Delaware (at least)."32

Both Acorda and Apicore therefore suggest that a plaintiff may satisfy personal jurisdiction by simply alleging an ANDA filing and an intent to distribute in light of that filing. Under this construct, it is up to the defendant to bring forward some fact demonstrating it does not have an intent to distribute in a jurisdiction. The Acorda line of cases thus may have put a thumb on the scale in favor of minimum contacts when the defendant has submitted an ANDA.


[1] Apicore US LLC v. Beloteca, Inc., No. 2:19-CV-00077-JRG, 2019 WL 1746079, at *2 n.5 (E.D. Tex. Apr. 18, 2019).

[2] Mylan Inst. LLC v. Aurobindo Pharma Ltd., 857 F.3d 858, 862 (Fed. Cir. 2017).

[3] Id.

[4] Id. at 862–63.

[5] Id. at 863.

[6] Id.; see Apicore, 2019 WL 1746079, at *1.

[7] Id.

[8] Id. at *2.

[9] Id. at *2 n.5.

[10] Mylan, 857 F.3d at 862.

[11] Apicore, 2019 WL 1746079, at *1.

[12] Id. at *2 n.6.

[13] Id.

[14] Id.

[15] Id. at *2.

[16] Acorda Therapeutics Inc. v. Mylan Pharms. Inc., 817 F.3d 755, at 760 (Fed. Cir. 2016).

[17] Apicore, 2019 WL 1746079, at *3.

[18] Id.

[19] Id. at *4.

[20] Id. at *3–*4.

[21] Id. at *4.

[22] Id. at *5.

[23] Id. at *7.

[24] Id.

[25] Id. at *7–*8.

[26] Id. at *4 n.9 (listing cases).

[27] Id. at *4 n.8.

[28] Id. at *4.

[29] See id. at *7 n.13.

[30] See id. at *4 n.9.

[31] Acorda, 817 F.3d at 760.

[32] Id. at 762.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions